Edition:
United States

Vernalis PLC (VER.L)

VER.L on London Stock Exchange

18.75GBp
26 May 2017
Change (% chg)

0.62 (+3.45%)
Prev Close
18.12
Open
17.50
Day's High
18.00
Day's Low
17.50
Volume
156,470
Avg. Vol
547,656
52-wk High
49.75
52-wk Low
16.00

Summary

Name Age Since Current Position

Peter Fellner

73 2009 Non-Executive Chairman of the Board

Ian Garland

48 2008 Chief Executive Officer, Executive Director

David Mackney

46 2009 Chief Financial Officer, Executive Director

Kevin Kissane

58 2010 Company Secretary

Ian Gilham

56 2015 Non-Executive Director

Lisa Schoenberg

48 2015 Non-Executive Director

Carol Ferguson

69 2011 Senior Independent Non-Executive Director

Nigel Sheail

48 2011 Non-Executive Independent Director

Biographies

Name Description

Peter Fellner

Dr. Peter J. Fellner Ph.D., is Non-Executive Chairman of the Board of Vernalis PLC. He was chairman of Celltech Group plc until its acquisition in mid-2004, having previously served as its chief executive officer from 1990 to 2003. Before Celltech he was chief executive officer of Roche UK, from 1986 to 1990. Dr Fellner is also chairman of the medical technology companies Consort Medical plc and Optos plc, and of the biotechnology companies Biotie Therapies Corp and Ablynx nv. In addition, he is a director of the global biopharmaceutical company, UCB SA, and serves as a member of the Novo A/S Advisory Group. He was previously chairman of Acambis plc and of Premier Research Group plc, until each was acquired during 2008 and was vice chairman of Astex Pharmaceuticals Inc until its sale in October 2013. He served as a director of Evotec AG, from 2005 to 2011, and QinetiQ Group plc from 2004 to 2009.

Ian Garland

Mr. Ian R. Garland is Chief Executive Officer, Executive Director of Vernalis PLC. From May 2007 until September 2008, he was chief executive officer of Acambis plc. During this period he oversaw a series of important advances culminating in Acambis’ acquisition by Sanofi-Aventis in September 2008 for £280 million. From 2004 to 2007, he served as chief financial officer of Arrow Therapeutics Ltd, a privately held company engaged in the discovery and development of new antiviral agents until its acquisition by AstraZeneca plc in February 2007 for US$150 million. Prior to this he was president and chief operating officer of Celltech Pharmaceuticals Inc, which had a turnover of around US$300 million, encompassing the US operations of Celltech Group plc. Mr Garland worked at KPMG between 1988 and 1995, specialising in the pharmaceutical sector, following qualification as a chartered accountant.

David Mackney

Mr. David Mackney is Chief Financial Officer, Executive Director of Vernalis PLC. Mr Mackney, a chartered accountant, was appointed as Chief Financial Officer on 2 February 2009. Prior to joining Vernalis he worked with Ian as interim chief financial officer at Acambis plc, successfully securing the US biodefence contract, the secondary financing and the acquisition of Acambis by Sanofi-Aventis. Prior to Acambis, he was chief financial officer for a private equity-backed technology company and served as group financial controller at Shire plc. From 1996 to 2001, he worked as a senior manager in audit and then in transaction services at Arthur Andersen.

Kevin Kissane

Mr. Kevin Kissane is Company Secretary of Vernalis PLC., since November 30, 2010. From July 2007 until May 2010, Mr Kissane was company secretary and group legal advisor of Antisoma plc. Prior to this, he was interim associate general counsel at UCB Celltech. Between 1990 and 2005, he held various posts within the legal function of Amersham plc (now part of GE Healthcare), the last being general counsel, Amersham Health. Following admission as a solicitor, Mr Kissane worked between 1979 and 1990 in private practice in the City.

Ian Gilham

Dr. Ian David Gilham is Non-Executive Director of the Company. Dr. Gilham has international experience in the research, development and commercialisation of diagnostic and pharmaceutical products. He is Non-Executive Chairman of a number of UK and European companies including Epistem Holdings Limited, Concepta Diagnostics Limited, Horizon Discovery Group plc, Multiplicom NV, and Biosurfit SA. Dr Gilham was formerly CEO of Axis-Sheild plc, a FTSE listed global diagnostics company. He also previously worked at GlaxoSmithKline as Vice President - Pharmacogenetics and before that held international general management, marketing business development and R&D positions with Abbott Laboratories, Celltech and Amersham.

Lisa Schoenberg

Ms. Lisa Amster Schoenberg has been appointed as Non-Executive Director of the Company, with effect from 1 September 2015. Ms. Schoenberg has extensive marketing experience of pharmaceutical products in both primary and secondary care in the US. For the past two years, she has acted as pharmaceutical marketing consultant to a number of organisations. From 1993 until 2013 Ms Schoenberg worked for AstraZeneca Pharmaceuticals (US) in a number of senior marketing positions, culminating as VP Sales & Marketing, Growth Brands USA. After graduating from the University of Michigan in 1988, Ms Schoenberg joined Amster & Co as Financial Analyst. She then undertook an MBA at Wharton School, University of Pennsylvania, specialising in Healthcare Management and Marketing, before joining AstraMerck in 1993. Ms Schoenberg is a trustee of the Shipley School and currently on the board of directors of the Jewish Family & Children Services Philadelphia.

Carol Ferguson

Ms. Carol C. Ferguson is Senior Independent Non-Executive Director of Vernalis PLC. Ms Ferguson was appointed as a non-executive director on 1 September 2003, having joined the Board of Vernalis Group plc as a non-executive director in May 2002. Vernalis Group plc was acquired by Vernalis plc (then called British Biotech plc) in September 2003. Ms Ferguson was appointed Chairman of the Audit Committee on 21 January 2004 and Senior Independent Director of the Company on 21 July 2011. She is a former partner and lead oil analyst at stockbrokers Wood Mackenzie and was finance director of a textiles company. She is currently non-executive chairman of BlackRock Greater Europe Investment Trust and Invesco Asia Trust plc and is non-executive director of a number of companies including Monks Investment Trust and Standard Life UK Smaller Companies Trust plc. She is also a director of the Chartered Accountants Compensation Scheme. She is a graduate of St Andrew’s University and a member of the Institute of Chartered Accountants of Scotland.

Nigel Sheail

Mr. Nigel Sheail is Non-Executive Independent Director of Vernalis PLC. He is head of business development and licensing for Bayer Healthcare. Prior to this he was head of Group M&A at Roche and head of licensing for their Pharma division. Mr Sheail has been responsible for a broad range of deals, from research and technology collaborations through to commercial product opportunities. Academically trained as a molecular biologist, he is a qualified chartered accountant and has held a number of roles within the pharmaceutical industry both with Roche and GSK. Mr Sheail has also worked as the global controller for research and was finance director responsible for the establishment of Roche’s operations in China which included five joint venture operating companies and a holding company. Mr Sheail was the founding treasurer of the Swiss Pharma Licensing Group.

Basic Compensation

Name Fiscal Year Total

Peter Fellner

105,000

Ian Garland

678,000

David Mackney

464,000

Kevin Kissane

--

Ian Gilham

--

Lisa Schoenberg

--

Carol Ferguson

--

Nigel Sheail

--
As Of  30 Dec 2013